AstraZeneca Lung Cancer Trial Results Delayed to 2027
The AVANZAR trial results are now set for early 2027 as researchers require more patient progression data.
Updated on Oct. 27, 2026 in Asthma
Live Poll
Is now a good time to invest in pharmaceutical companies based on future drug trials?
AstraZeneca has rescheduled the release of findings from its AVANZAR lung cancer trial to the first quarter of 2027. The postponement was driven by a current lack of sufficient patient disease progression data to finalize the study results.
Why it matters
The AVANZAR trial is a key project for the company, as successful results in 2027 could influence long-term growth and unlock over $20 billion in peak sales. The delay highlights the complexities of gathering clear progression metrics in oncology research.
The AVANZAR study, an oncology trial evaluating Datroway, has been delayed due to insufficient patient disease progression data. Outcomes are now expected in the first quarter of 2027, which is a shift from the initially scheduled final quarter of 2026.
The players
AstraZeneca
A global pharmaceutical company specializing in oncology, respiratory, and rare disease therapies.
JP Morgan
A global financial services firm that evaluates pharmaceutical pipelines and investment potential.
The details
The trial evaluates Datroway, a therapeutic agent currently under development for lung cancer. Scientists are assessing success probabilities by measuring specific biomarker-positive groups against total patient populations. The timeline shift was necessitated because current data does not yet meet the required statistical hurdles to report meaningful progression outcomes.
Timeline
October 2026: AstraZeneca presented at the European Society for Medical Oncology congress.
Q4 2026: Original release date for the AVANZAR trial results.
Q1 2027: Revised release date for the AVANZAR trial findings.
2027: Scheduled release window for multiple major late-stage trials.
2027-2030: Period for projected 10% annual core earnings growth.
Health Landscape
This delay occurs within a broader industry push to leverage novel biomarkers in late-stage oncology trials to identify high-responding patient populations. Such trials are central to the current development pipeline, which aims to secure growth through 2030.
While this delay specifically concerns trial data, patients following new lung cancer treatments should be aware that clinical timelines are often subject to change as researchers gather more precise progression data. It is always worth discussing new therapy developments with an oncologist.
The takeaway
Reliable clinical data is the foundation of new cancer treatments, and trial delays often reflect the rigor required to ensure safety and efficacy. Patients are encouraged to track major study readouts with their physician to understand how new findings may eventually impact standard care.
Further reading
Learn more about the latest research in our Asthma section.
Source note: This article includes information reported by The Market Reporter.
Live Poll
Is now a good time to invest in pharmaceutical companies based on future drug trials?
